ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN-267

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 28, 2022 12:17pm

117 Views

Post# 34639289

RE:PMN-267

Any PMN267 milestone reached is good news, but the statements from Cashman and Altsteil could hardly be more bland. If you're going to make a news release out of it how about quantifying "moved forward as rapidly as possible"? You call it a milestone reached, well then what's the next one?
As is it looks as much contrived to let Larry issue his first official words, whoopee.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks